Why brokers give the Ramsay Health (ASX:RHC) share price a thumbs up

Although the Ramsay share price has been volatile of late, brokers seem to see plenty of upside. Here's why.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ramsay Health Care Limited (ASX: RHC) share price has been on a rollercoaster ride recently.

Shares in the health care company reached a high of $69.49 in November only to fall as low as $58.71 in January. At the time of writing, the Ramsay Health share is trading at $63.66, up 2.22%.

Despite the volatility, it appears that brokers are positive about the future of the company. We take a look at some of the reasons why. 

positive asx share price represented by lots of hands all making thumbs up gesture

Image source: Getty Images

A major acquisition

Ramsay Health Care announced last month that it was putting a cash offer to acquire the UK-based Spire Group. Spire is an independent hospital group focused on the private patient market and a leading provider of high-acuity care.

The UK acquisition appears to be a logical step for Australia's largest private hospital provider.

As described in its company literature, Ramsay "provides quality health care through a global network of clinical practice, teaching and research". The company says its global network extends across 10 countries, with more than eight million admissions/patient visits to its facilities in more than 460 locations.

Which brokers are positive on the company?

Citi Bank yesterday upgraded Ramsay Health Care to a buy.  The broker attributed to rating upgrade to the recent fall in the Ramsay share price and the fact that company has underperformed the ASX 200 by 14% in the last quarter. 

Citi expects an big upside with the Spire acquisition, COVID-19 restrictions being lifted and hospitals getting back to normal.

Analysts at Macquarie are also positive about the healthcare company.  Macquarie has retained its outperform rating and $74.85 price target on Ramsay Health Care.

Macquarie believes that the Spire deal stems well for the Ramsay share price and long term growth in the lucrative UK market.

With the Ramsay share price currently trading around $63, Macquarie's price target is a whopping 20% upgrade on the current price.

.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »